How can I tell a counterfeit from packaging?

Generally you cannot. Packaging is the easiest part to reproduce convincingly. Batch-matched analytical data is the only check that reflects what is actually in the vial.

What does a mass spectrometry result tell me?

It confirms identity — that the observed molecular mass corresponds to the expected sequence. It does not by itself tell you how pure the sample is.

Is a supplier's own certificate enough?

An in-house certificate is weaker evidence than an independent one. Independence of the issuing laboratory is part of what makes the document meaningful.

Research & Regulatory News

Counterfeit GLP-1 Products: The 2026 UK Picture

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-222 cited sources

Demand for incretin compounds has produced a substantial counterfeit market. The MHRA has seized counterfeit GLP-1 pens and closed an unlicensed manufacturing facility, and US poison centres reported a 265% rise in related exposures. For anyone sourcing material, third-party analytical verification is the only meaningful check.

Key facts

MHRA action: Counterfeit pen seizures; unlicensed facility closed
US poison-centre exposures: Reported 265% rise
Primary risk: Unknown identity, purity and content
Practical check: Batch-specific third-party CoA
Identity method: Mass spectrometry
Purity method: Reverse-phase HPLC

What the counterfeit market actually looks like

Counterfeiting has followed demand into the incretin space, and the failure modes are not exotic. Product may contain a different compound entirely, a fraction of the stated content, or material of unknown purity carrying synthesis by-products. Presentation is frequently convincing; packaging and holograms are much easier to reproduce than the molecule inside.

Why certificates are the practical defence

A certificate of analysis is only worth anything if it is batch-specific, issued by an independent laboratory, and matched to the lot number on the vial in front of you. A generic certificate with no batch reference proves nothing about the material you hold. The two analyses that matter are mass spectrometry, which confirms the compound is what it claims to be, and reverse-phase HPLC, which quantifies how much of the sample is that compound rather than something else.

Reading a certificate properly

Check that the batch number matches the vial. Check the issuing laboratory is independent of the supplier. Check the observed mass against the theoretical mass for the sequence. Check the HPLC purity figure and, just as importantly, look at whether the chromatogram is shown at all — a purity number with no trace behind it is an assertion, not a measurement.

Batch number on the certificate matches the batch on the vial
Issuing laboratory is independent of the supplier
Observed mass matches theoretical mass for the stated sequence
HPLC purity is supported by a visible chromatogram, not just a figure
Date of issue is consistent with the batch, not years old

Why this matters more for incretins than for other compounds

Two reasons. Incretin peptides carry the highest unit value in the category, which is what attracts counterfeiting in the first place. And retatrutide in particular has no licensed product anywhere in the world, so there is no authorised reference presentation to compare an unfamiliar vial against.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

How can I tell a counterfeit from packaging?: Generally you cannot. Packaging is the easiest part to reproduce convincingly. Batch-matched analytical data is the only check that reflects what is actually in the vial.
What does a mass spectrometry result tell me?: It confirms identity — that the observed molecular mass corresponds to the expected sequence. It does not by itself tell you how pure the sample is.
Is a supplier's own certificate enough?: An in-house certificate is weaker evidence than an independent one. Independence of the issuing laboratory is part of what makes the document meaningful.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum